PL2794882T3 - MikroRNA do regeneracji serca poprzez indukowanie proliferacji miocytów serca - Google Patents

MikroRNA do regeneracji serca poprzez indukowanie proliferacji miocytów serca

Info

Publication number
PL2794882T3
PL2794882T3 PL12823043T PL12823043T PL2794882T3 PL 2794882 T3 PL2794882 T3 PL 2794882T3 PL 12823043 T PL12823043 T PL 12823043T PL 12823043 T PL12823043 T PL 12823043T PL 2794882 T3 PL2794882 T3 PL 2794882T3
Authority
PL
Poland
Prior art keywords
cardiac
microrna
inducing
regeneration
myocyte proliferation
Prior art date
Application number
PL12823043T
Other languages
English (en)
Inventor
Mauro Giacca
Serena Zacchigna
Mano Miguel Luis Cunha
Eulalio Ana Sofia Bregieiro
Original Assignee
I.C.G.E.B. International Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I.C.G.E.B. International Centre For Genetic Engineering And Biotechnology filed Critical I.C.G.E.B. International Centre For Genetic Engineering And Biotechnology
Publication of PL2794882T3 publication Critical patent/PL2794882T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
PL12823043T 2011-12-23 2012-12-21 MikroRNA do regeneracji serca poprzez indukowanie proliferacji miocytów serca PL2794882T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000685A ITRM20110685A1 (it) 2011-12-23 2011-12-23 Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP12823043.0A EP2794882B1 (en) 2011-12-23 2012-12-21 Micrornas for cardiac regeneration through induction of cardiac myocyte proliferation
PCT/IB2012/057590 WO2013093870A1 (en) 2011-12-23 2012-12-21 microRNAs FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION

Publications (1)

Publication Number Publication Date
PL2794882T3 true PL2794882T3 (pl) 2018-03-30

Family

ID=45614969

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12823043T PL2794882T3 (pl) 2011-12-23 2012-12-21 MikroRNA do regeneracji serca poprzez indukowanie proliferacji miocytów serca

Country Status (8)

Country Link
US (5) US10337002B2 (pl)
EP (1) EP2794882B1 (pl)
JP (2) JP6153538B2 (pl)
DK (1) DK2794882T3 (pl)
ES (1) ES2644574T3 (pl)
IT (1) ITRM20110685A1 (pl)
PL (1) PL2794882T3 (pl)
WO (1) WO2013093870A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP3628334B1 (en) 2014-03-21 2023-06-28 Genzyme Corporation Gene therapy for retinitis pigmentosa
ES2769030T3 (es) * 2014-05-16 2020-06-24 Univ Pennsylvania Inducción por microARN de la regeneración cardíaca
DE102015216782B3 (de) * 2015-09-02 2017-01-26 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Verwendung von im Blutserum oder Blutplasma zirkulierenden microRNAs zur Identifikation biopsiepflichtiger Patienten und als Marker zur Differentialdiagnose einzelner nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens
TWI685500B (zh) * 2015-10-13 2020-02-21 長庚大學 以微核酸-５２０ｂ（ｍｉＲ-５２０ｂ）序列作爲抑制頭頸癌腫瘤生長、侵犯與轉移及其醫藥組成物之用途
EP3507595B8 (en) * 2016-06-17 2024-03-06 Massachusetts Institute of Technology Chemiresistor with carbon nanotube composite for wireless chemical sensing
EP3375458A1 (en) 2017-03-14 2018-09-19 I.C.G.E.B. International Centre for Genetic Engineering and Biotechnology Microrna hsa-mir-665 in cardiac hypertrophy
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
EP3936616A1 (en) 2020-07-10 2022-01-12 Charité - Universitätsmedizin Berlin Microrna-targeted therapy for cardiac repair
CN112680509A (zh) * 2021-01-20 2021-04-20 河南省中医院（河南中医药大学第二附属医院） 一种评估冠心病预后分子标志物miR-302e及其逆转录引物、扩增引物和应用
CN114958849B (zh) * 2022-05-26 2023-10-27 华南农业大学 lncRNACACF吸附miR-520b-3p在调控人脐静脉内皮细胞周期中的应用
WO2025253097A1 (en) 2024-06-03 2025-12-11 Forcefield Therapeutics Limited Proteins with cardiopreservation activity

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7380126B2 (en) 2001-06-01 2008-05-27 Logan James D Methods and apparatus for controlling the transmission and receipt of email messages
JP4371812B2 (ja) * 2001-09-28 2009-11-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ マイクロｒｎａ分子
WO2005078096A2 (en) 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
EP2322650A1 (en) 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
EP2290072B1 (en) 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
WO2007148235A2 (en) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Cancer-related nucleic acids
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US8592384B2 (en) 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
EP2377559A1 (en) 2005-06-03 2011-10-19 Southern Adelaide Health Service - Flinders Medical Centre Targeting cells with altered microRNA expression
CN101341259B (zh) 2005-08-01 2011-12-21 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
ES2429404T3 (es) * 2006-01-05 2013-11-14 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
CA2660204A1 (en) * 2006-08-16 2008-02-21 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
WO2008042231A2 (en) 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
AU2007306594A1 (en) 2006-10-09 2008-04-17 Julius-Maximilians-Universitat Wurzburg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2008063919A2 (en) 2006-11-10 2008-05-29 The Uab Research Foundation A microrna mediator of cardiomyopathy and heart failure
EP2134842A2 (en) 2007-03-07 2009-12-23 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
BRPI0813527A2 (pt) 2007-07-18 2014-12-30 Univ Colorado Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
WO2009099465A2 (en) * 2007-08-14 2009-08-13 Yale University Methods of using mir-199a as a marker and sequences of mir-199a as a therapeutic for cancer
AU2008289447B2 (en) 2007-08-22 2014-09-04 Trovagene, Inc. Methods of using miRNA for detection of in vivo cell death
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
JP5626619B2 (ja) 2008-12-08 2014-11-19 国立大学法人京都大学 効率的な核初期化方法
EP2238251B1 (en) 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing of polo-like kinase expression using interfering rna
AU2009207291B2 (en) 2008-01-27 2014-11-06 Mor Research Applications Methods and compositions for diagnosing complications of pregnancy
CN105734128B (zh) 2008-02-01 2021-05-18 总医院有限公司 微泡在医学疾病和病况的诊断、预后以及治疗中的用途
CA2714410A1 (en) 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
WO2009105759A2 (en) 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
AU2009215934C1 (en) * 2008-02-22 2014-05-08 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
WO2009114681A2 (en) 2008-03-13 2009-09-17 Dharmacon, Inc. Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
US8258111B2 (en) * 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2009143379A2 (en) 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
US20110152352A1 (en) 2008-06-10 2011-06-23 Tufts University Smad proteins control drosha-mediated mirna maturation
AU2009270005B2 (en) 2008-06-16 2014-07-24 Academisch Ziekenhuis Maastricht Means and methods for counteracting, delaying and/or preventing heart disease
US20100003674A1 (en) 2008-07-03 2010-01-07 Cope Frederick O Adult stem cells, molecular signatures, and applications in the evaluation, diagnosis, and therapy of mammalian conditions
WO2010033871A2 (en) 2008-09-18 2010-03-25 The Johns Hopkins University Compositions and methods targeting glutaminase
CA2743566C (en) * 2008-11-19 2021-11-09 Anthrogenesis Corporation Amnion derived adherent cells
EP2208785A1 (en) * 2009-01-15 2010-07-21 Newbiotechnic, S.A. Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
AU2010207975B2 (en) 2009-02-02 2016-04-28 Cepheid Methods of detecting sepsis
US20110086348A1 (en) 2009-02-19 2011-04-14 The Cleveland Clinic Foundation Method for assessing heart disease
SG174150A1 (en) 2009-02-24 2011-10-28 Scripps Research Inst Reengineering mrna primary structure for enhanced protein production
EP2228444A1 (en) 2009-03-09 2010-09-15 Julius-Maximilians-Universität Würzburg microRNA for diagnostic and therapeutic purposes in cardiovascular diseases
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
WO2010117860A2 (en) 2009-04-06 2010-10-14 The Board Of Regents Of The University Of Texas System Microrna signature to predict prognosis in heart failure
CA2757517A1 (en) * 2009-04-07 2010-10-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
WO2010120969A1 (en) * 2009-04-15 2010-10-21 Board Of Regents, The University Of Texas System Targeting of the mir-30 family and let-7 family as a treatment for heart disease
WO2010126355A1 (en) * 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
SG175821A1 (en) 2009-04-29 2011-12-29 Academisch Medisch Ct Bij De Univeriteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
WO2010129950A1 (en) 2009-05-08 2010-11-11 Board Of Regents, The University Of Texas System Micro-rna that regulates cardiac remodeling
US9072765B2 (en) 2009-05-20 2015-07-07 Board Of Regents, The University Of Texas System Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
US8815822B2 (en) 2009-08-06 2014-08-26 Universiteit Maastricht Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
CN101643791A (zh) 2009-09-04 2010-02-10 哈尔滨医科大学 microRNA-328及其反义核苷酸在诊断、防治心脏疾病中的用途
US9078914B2 (en) 2009-09-10 2015-07-14 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
EP2305810A1 (en) 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
AR078584A1 (es) 2009-10-09 2011-11-16 Baylor Res Inst Identificacion de microarn (miarn) en muestras fecales como biomarcador de canceres gastroenterologicos
SG2014010698A (en) 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states
CA2783536A1 (en) 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
DE102010004722B4 (de) * 2010-01-15 2013-05-08 Maschinenfabrik Köppern Gmbh & Co. Kg Verschleißbeständiger, warmfester Werkstoff, sowie dessen Verwendung
EP2842577A1 (en) 2010-03-12 2015-03-04 Daiichi Sankyo Company, Limited Method for proliferating cardiomyocytes using micro-RNA
ES2743600T3 (es) 2010-03-12 2020-02-20 Brigham & Womens Hospital Inc Métodos de tratamiento de los trastornos inflamatorios vasculares
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US9115345B2 (en) 2010-04-19 2015-08-25 The Trustees Of The University Of Pennsylvania MicroRNA induction of pluripotential stem cells and uses thereof
CN102884206B (zh) 2010-04-21 2014-07-30 阿姆斯特丹大学学术医学中心 用于确定心血管疾病的风险的手段和方法
EP2580328A2 (en) * 2010-06-11 2013-04-17 Cellartis AB Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
GB201012272D0 (en) 2010-07-21 2010-09-08 Univ Coventry Assays for screening drug safety
EP2598158A4 (en) 2010-07-28 2014-03-12 Inst Cardiologie Montreal Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
EP2603592A2 (en) 2010-08-13 2013-06-19 The University Court of the University of Glasgow Therapeutic uses of microvesicles and related micrornas
US20130150431A1 (en) 2010-08-27 2013-06-13 New York University Mir-33 inhibitors and uses thereof
WO2012048236A1 (en) 2010-10-08 2012-04-12 Baylor Research Institute Micrornas (mirna) as biomakers for the identification of familial and non-familial colorectal cancer
US20120093885A1 (en) 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
WO2012052953A1 (en) 2010-10-20 2012-04-26 Fondazione Centro San Raffaele Del Monte Tabor MiRNA
EP2446929A1 (en) * 2010-10-27 2012-05-02 Johann Wolfgang Goethe-Universität Frankfurt am Main Microvesicles derived from atheroprotective endothelial cells for the treatment and prevention of atherosclerotic diseases
CA2817002C (en) 2010-11-05 2019-01-15 Miragen Therapeutics Base modified oligonucleotides
CA2819378A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
WO2012083004A2 (en) 2010-12-15 2012-06-21 Miragen Therapeutics Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions
WO2012094366A1 (en) 2011-01-06 2012-07-12 Cardiodx, Inc. Circulating mirnas as biomarkers for coronary artery disease
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
EP2681336A4 (en) 2011-03-02 2014-11-19 Groove Biopharma Corp ENHANCED BIODISTRIBUTION OF OLIGOMERS
WO2012122447A1 (en) 2011-03-09 2012-09-13 The Brigham And Women's Hospital, Inc. Methods of using microrna-26a to promote angiogenesis
WO2012149557A1 (en) 2011-04-28 2012-11-01 New York University miR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION
ES2703133T3 (es) 2011-05-24 2019-03-07 Rosetta Genomics Ltd Métodos y composiciones para determinar insuficiencia cardiaca o un riesgo de insuficiencia cardiaca
WO2013048734A1 (en) * 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci

Also Published As

Publication number Publication date
JP6153538B2 (ja) 2017-06-28
DK2794882T3 (en) 2017-10-30
US12391943B2 (en) 2025-08-19
US11236332B2 (en) 2022-02-01
JP2015502976A (ja) 2015-01-29
ES2644574T3 (es) 2017-11-29
US20240240184A1 (en) 2024-07-18
JP2017186339A (ja) 2017-10-12
US20250361509A1 (en) 2025-11-27
ITRM20110685A1 (it) 2013-06-24
US20190256850A1 (en) 2019-08-22
JP6420865B2 (ja) 2018-11-07
US20150011609A1 (en) 2015-01-08
EP2794882B1 (en) 2017-07-26
US10337002B2 (en) 2019-07-02
EP2794882A1 (en) 2014-10-29
WO2013093870A1 (en) 2013-06-27
US20220228143A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
PL2794882T3 (pl) MikroRNA do regeneracji serca poprzez indukowanie proliferacji miocytów serca
HUE036588T2 (hu) Eljárások HCV kezelésére
EP2790771A4 (en) LUER CONNECTOR
BR112014002399A2 (pt) conjunto
EP2675329A4 (en) POSITION OF AN OVEN
EP2692380A4 (en) SYRINGE
BR112014010169A2 (pt) derivado n-tienilbenzamida substituída com aminoalquil
EP2766407A4 (en) PENTA BLOCK POLYMERS
BR112014009795A2 (pt) método
BR112014007958A2 (pt) método
FR2972772B1 (fr) Generateur hydrolien
BR112014001765A2 (pt) método
BR112014001237A2 (pt) método
LT3395357T (lt) Kompozicija, skirta kontroliuojamai kiaušidžių stimuliacijai
PT2750709T (pt) Tratamento da caquexia
BR112013022820A2 (pt) método de tratamento
EP2794841A4 (en) BIOREACTOR
FI20116167L (fi) Järjestely
CO6880064A2 (es) Métodos terapéuticos
DK3369742T3 (da) Dimere bakteriofaglysiner
EP2752241A4 (en) CATALYST
DK2478758T3 (da) Fordelermaskine
CO6821930A2 (es) Métodos de tratamiento de biomasa
IL228729A0 (en) Treatment regimens
UA23002S (uk) Ніж